Source:http://linkedlifedata.com/resource/pubmed/id/20401438
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2010-4-19
|
| pubmed:abstractText |
Recombinant human thyrotropin (rhTSH) reduces the activity of radioiodine required to treat multinodular goiter (MNG), but acute airway compression can be a life-threatening complication. In this prospective, randomized, double-blind, placebo-controlled study, we assessed the efficacy and safety (including airway compression) of different doses of rhTSH associated with a fixed activity of 131I for treating MNG. Euthyroid patients with MNG (69.3 +/- 62.0 mL, 20 females, 2 males, 64 +/- 7 years) received 0.1 mg (group I, N = 8) or 0.01 mg (group II, N = 6) rhTSH or placebo (group III, N = 8), 24 h before 1.11 GBq 131I. Radioactive iodine uptake was determined at baseline and 24 h after rhTSH and thyroid volume (TV, baseline and 6 and 12 months after treatment) and tracheal cross-sectional area (TCA, baseline and 2, 7, 180, and 360 days after rhTSH) were determined by magnetic resonance; antithyroid antibodies and thyroid hormones were determined at frequent intervals. After 6 months, TV decreased significantly in groups I (28.5 +/- 17.6%) and II (21.6 +/- 17.8%), but not in group III (2.7 +/- 15.3%). After 12 months, TV decreased significantly in groups I (36.7 +/- 18.1%) and II (37.4 +/- 27.1%), but not in group III (19.0 +/- 24.3%). No significant changes in TCA were observed. T3 and free T4 increased transiently during the first month. After 12 months, 7 patients were hypothyroid (N = 3 in group I and N = 2 in groups II and III). rhTSH plus a 1.11-GBq fixed 131I activity did not cause acute or chronic changes in TCA. After 6 and 12 months, TV reduction was more pronounced among patients treated with rhTSH plus 131I.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
1414-431X
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
43
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
303-9
|
| pubmed:meshHeading |
pubmed-meshheading:20401438-Adult,
pubmed-meshheading:20401438-Aged,
pubmed-meshheading:20401438-Airway Obstruction,
pubmed-meshheading:20401438-Autoantibodies,
pubmed-meshheading:20401438-Combined Modality Therapy,
pubmed-meshheading:20401438-Double-Blind Method,
pubmed-meshheading:20401438-Female,
pubmed-meshheading:20401438-Goiter, Nodular,
pubmed-meshheading:20401438-Humans,
pubmed-meshheading:20401438-Iodine Radioisotopes,
pubmed-meshheading:20401438-Magnetic Resonance Imaging,
pubmed-meshheading:20401438-Male,
pubmed-meshheading:20401438-Middle Aged,
pubmed-meshheading:20401438-Prospective Studies,
pubmed-meshheading:20401438-Recombinant Proteins,
pubmed-meshheading:20401438-Thyroid Function Tests,
pubmed-meshheading:20401438-Thyrotropin,
pubmed-meshheading:20401438-Treatment Outcome
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
Radioiodine plus recombinant human thyrotropin do not cause acute airway compression and are effective in reducing multinodular goiter.
|
| pubmed:affiliation |
Instituto de Diabetes e Endocrinologia de Maringá, PR, Brasil. ccalbino@uol.com.br
|
| pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|